SAKK 24/09: Safety and tolerability of bevacizumab plus paclitaxel versus bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer—A multicenter, randomized phase III trial.
Christoph Rochlitz, Ralph C. Winterhalder(Luzerner Kantonsspital), Daniel Rauch(Washington University in St. Louis), Andreas Trojan(Immunologie-Zentrum Zürich), Roger von Moos(Kantonsspital Graubünden), Tamara Rordorf(Institut Gustave Roussy), Daniela Baertschi(Swiss Group For Clinical Cancer Research), Ursula Hasler-Strub(Kantonsspital Graubünden), Sandro Anchisi(Hôpital du Valais), Andreas Mueller(Kantonsspital Winterthur), Khalil Zaman, Richard Cathomas(Kantonsspital Graubünden), Marc Küng(HFR Freiburg Kantonsspital), Kyung Jae Na(Novartis (Switzerland)), Martin Bigler(Swiss Group For Clinical Cancer Research), Markus Borner(University of Bern), Marcus Vetter(University Hospital of Basel), J. Bernhard(International Breast Cancer Study Group), Thomas Ruhstaller(University Hospital Bonn)
Cited by 14
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines
|European Urology|2020|2.2k